Hun Ju Lee, MD, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory mantle cell lymphoma.
Hun Ju Lee, MD, an associate professor of medicine in the Department of Lymphoma & Myeloma and the Jessica and Jeffrey Brue Endowed Professor of Lymphoma Research at The University of Texas MD Anderson Cancer Center, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib (Imbruvica) in patients with relapsed/refractory mantle cell lymphoma (MCL).
At the 2020 ASCO Virtual Scientific Program, interim results showed that the combination led to an 83.3% overall response rate in 12 patients with relapsed/refractory MCL, says Lee. Moreover, 7 patients achieved a complete response, and 3 patients achieved a partial response.
Additionally, of the 7 patients who achieved a CR, 2 had progressed on rituximab (Rituxan)/ibrutinib and rituximab/ hyperfractionated cyclophosphamide, vincristine, doxorubicin hydrochloride, and dexamethasone, 1 patient previously underwent an autologous stem cell transplant and an allogeneic stem cell transplant (allo-SCT), and 1 patient underwent an allo-SCT and received CAR T-cell therapy.
Additionally, only grade 1/2 adverse effects related to cirmtuzumab were noted, and the safety profile of ibrutinib was as expected, concludes Lee.